We investigated the factors affecting PD-L1 shifting (negative → positive) in the initial PD-L1-negative patients (n = 32) in the upfront surgery group because chemotherapy could alter the biology of the residual tumor and tumor microenvironment [14,15,16], affecting the PD-L1 status of surgical specimens after NACT. The gene discussed is CD274; the disease is neoplasm.